Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines

Autoimmune T and B cell responses to CNS antigen(s) are thought to drive the pathogenesis of multiple sclerosis (MS), and thus are logical targets for therapy. Indeed, several immunomodulatory agents, including IFN-β1b, IFN-β1a, glatiramer acetate, and mitoxantrone, have had beneficial clinical effects in different forms of MS. However, because the available treatments are only partially effective, MS therapy needs to be further improved. Selective (antigen-specific) immunotherapies are especially appealing because in theory they combine maximal efficacy with minimal side effects. Indeed, several innovative immunotherapies have been successfully applied in experimental autoimmune encephalomyelitis. For example, autoreactive T cells can be selectively targeted by means of antigen, T cell receptor, or activation markers. However, experimental autoimmune encephalomyelitis is far from being a perfect approximation of MS because MS is more heterogeneous and the target antigen(s) is (are) not known. Further advances in MS therapy will depend on our growing understanding of the pathogenesis of this still incurable disease.

[1]  Rebecca Zerzan "Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis". , 2005, Discovery medicine.

[2]  L. Wilkinson Immunity , 1891, The Lancet.

[3]  M. Duddy,et al.  Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1 , 2004, The Journal of Immunology.

[4]  C. Farina,et al.  Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. , 2004, Brain : a journal of neurology.

[5]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[6]  B. Trapp Pathogenesis of multiple sclerosis: The eyes only see what the mind is prepared to comprehend , 2004, Annals of neurology.

[7]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[8]  R. Simon,et al.  Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis , 2004, The Journal of Immunology.

[9]  K. Toyka,et al.  Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate , 2004, Journal of Neuroimmunology.

[10]  K. Rajewsky,et al.  Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Arthur A. Vandenbark,et al.  TCR Peptide Therapy in Human Autoimmune Diseases , 2001, Neurochemical Research.

[12]  H. Weiner Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis , 2004 .

[13]  A. Achiron,et al.  T-cell vaccination in multiple sclerosis. , 2004, Autoimmunity Reviews.

[14]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[15]  M. Sela,et al.  Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Hohlfeld,et al.  T-cell-mediated autoimmunity - Novel techniques to characterize autoreactive T-cell receptors , 2003 .

[17]  D. Gilden,et al.  Single-Cell Repertoire Analysis Demonstrates that Clonal Expansion Is a Prominent Feature of the B Cell Response in Multiple Sclerosis Cerebrospinal Fluid 1 , 2003, The Journal of Immunology.

[18]  C. Polman,et al.  New and emerging treatment options for multiple sclerosis , 2003, The Lancet Neurology.

[19]  Lawrence Steinman,et al.  Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis , 2003, Nature Biotechnology.

[20]  M. Zhan,et al.  Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype , 2003, Journal of Neuroimmunology.

[21]  G. Martino,et al.  The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. , 2003, Current opinion in neurology.

[22]  Lawrence Steinman,et al.  Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year , 2003, The Journal of experimental medicine.

[23]  M. Kapsenberg,et al.  Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1 , 2003, The Journal of Immunology.

[24]  H. Hartung,et al.  Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. , 2003, Trends in pharmacological sciences.

[25]  R. Hohlfeld,et al.  Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases , 2003, Annals of neurology.

[26]  Leonard C. Harrison,et al.  Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity , 2003, Nature Reviews Immunology.

[27]  J. Bach Regulatory lymphocytes: Regulatory T cells under scrutiny , 2003, Nature Reviews Immunology.

[28]  N. Hellings,et al.  T cell vaccination in multiple sclerosis patients with autologous CSF‐derived activated T cells: results from a pilot study , 2003, Clinical and experimental immunology.

[29]  L. Peltonen,et al.  Aire regulates negative selection of organ-specific T cells , 2003, Nature Immunology.

[30]  C. Farina,et al.  Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis , 2002, Journal of Neurology.

[31]  R. Hohlfeld,et al.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.

[32]  Arne Svejgaard,et al.  A functional and structural basis for TCR cross-reactivity in multiple sclerosis , 2002, Nature Immunology.

[33]  A. Bar-Or,et al.  Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. , 2002, Clinical immunology.

[34]  H. Neumann,et al.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases , 2002, Trends in Neurosciences.

[35]  Massimo Filippi,et al.  MRI techniques to monitor MS evolution: The present and the future , 2002, Neurology.

[36]  F. Barkhof,et al.  Antibody‐mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial , 2002, Annals of neurology.

[37]  H. Hartung,et al.  New concepts in the immunopathogenesis of multiple sclerosis , 2002, Nature Reviews Neuroscience.

[38]  P. Brown,et al.  Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.

[39]  C. Farina,et al.  Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients , 2002, Journal of Neuroimmunology.

[40]  V. Rivera,et al.  T cell vaccination in multiple sclerosis: results of a preliminary study , 2002, Journal of Neurology.

[41]  D S Goodin,et al.  Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines , 2002, Neurology.

[42]  Manjit,et al.  Neurology , 1912, NeuroImage.

[43]  W. Brück,et al.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? , 2002, Brain : a journal of neurology.

[44]  H. Link,et al.  Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis , 2001, Journal of Neuroimmunology.

[45]  H. McFarland,et al.  CD4+CD28- costimulation-independent T cells in multiple sclerosis. , 2001, The Journal of clinical investigation.

[46]  Pablo Villoslada,et al.  Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates , 2001, European journal of immunology.

[47]  J. Goverman,et al.  A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis , 2001, The Journal of experimental medicine.

[48]  Roland Martin,et al.  Immunotherapy of multiple sclerosis: Where are we? Where should we go? , 2001, Nature Immunology.

[49]  M. A. Curotto de Lafaille,et al.  Regulatory T cells in spontaneous autoimmune encephalomyelitis , 2001, Immunological reviews.

[50]  P. Fontoura,et al.  Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. , 2001, Immunity.

[51]  H. Wekerle,et al.  Myelin Antigen-Specific CD8+ T Cells Are Encephalitogenic and Produce Severe Disease in C57BL/6 Mice1 , 2001, The Journal of Immunology.

[52]  H. Lassmann,et al.  Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. , 2001, Immunity.

[53]  R. Moss,et al.  Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. , 2001, Journal of neuroscience research.

[54]  M. Sela,et al.  Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® , 2001, Journal of Neuroimmunology.

[55]  C. Farina,et al.  Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. , 2001, Brain : a journal of neurology.

[56]  C. Farina,et al.  Mechanisms of action of glatiramer acetate in multiple sclerosis , 2001, Neurology.

[57]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[58]  C. Lucchinetti,et al.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.

[59]  H. Neumann,et al.  Anti‐inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration , 2001, European journal of immunology.

[60]  R. Martin,et al.  Mechanisms of immunomodulation by glatiramer acetate , 2000, Neurology.

[61]  H. Wekerle,et al.  Myelin oligodendrocyte glycoprotein‐DNA vaccination induces antibody‐mediated autoaggression in experimental autoimmune encephalomyelitis , 2000, European journal of immunology.

[62]  J. Antel,et al.  NBI‐5788, an altered MBP83‐99 peptide, induces a T‐helper 2–like immune response in multiple sclerosis patients , 2000, Annals of neurology.

[63]  H. Weiner,et al.  Oral tolerance, an active immunologic process mediated by multiple mechanisms. , 2000, The Journal of clinical investigation.

[64]  I. Catz,et al.  Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients , 2000, Multiple sclerosis.

[65]  A. Evans,et al.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.

[66]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[67]  Hans Lassmann,et al.  Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction , 2000, The Journal of experimental medicine.

[68]  G. Barger,et al.  Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years , 2000, Multiple sclerosis.

[69]  L. Weiner,et al.  T cell vaccination in secondary progressive multiple sclerosis , 2000, Journal of Neuroimmunology.

[70]  C. Farina,et al.  Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  L. Steinman Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. , 2000, Journal of autoimmunity.

[72]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[73]  Jingwu Z. Zhang,et al.  Preferential Recognition of TCR Hypervariable Regions by Human Anti-Idiotypic T Cells Induced by T Cell Vaccination1 , 2000, The Journal of Immunology.

[74]  J. Krieger,et al.  Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. , 2000, The Journal of clinical investigation.

[75]  R. Hohlfeld,et al.  Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. , 2000, Brain : a journal of neurology.

[76]  N. Chiorazzi,et al.  Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.

[77]  T. Olsson,et al.  Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Stinissen,et al.  Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations , 2000, Journal of Neuroimmunology.

[79]  Roland Martin,et al.  Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7 , 1999, Journal of Neuroimmunology.

[80]  S. Baranzini,et al.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. , 1999, Journal of immunology.

[81]  L. Fugger,et al.  A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor , 1999, Nature Genetics.

[82]  P. Stinissen,et al.  Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. , 1999, Journal of autoimmunity.

[83]  H. Wekerle,et al.  Gene transfer into CD4+ T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses , 1999, Nature Medicine.

[84]  E. Meinl,et al.  Concepts of viral pathogenesis of multiple sclerosis. , 1999, Current opinion in neurology.

[85]  S. Schmidt Candidate autoantigens in multiple sclerosis , 1999, Multiple sclerosis.

[86]  Roland Martin,et al.  Molecular mimicry and multiple sclerosis: Degenerate T‐cell recognition and the induction of autoimmunity , 1999, Annals of neurology.

[87]  H. Weiner Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  H. Garren,et al.  Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. , 1999, Journal of immunology.

[89]  Irun R. Cohen,et al.  Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.

[90]  M. Sela,et al.  Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 , 1998, Journal of Neuroimmunology.

[91]  Y. Qin,et al.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. , 1998, The Journal of clinical investigation.

[92]  F. Zipp,et al.  Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. , 1998, Brain : a journal of neurology.

[93]  H. Wekerle The viral triggering of autoimmune disease , 1998, Nature Medicine.

[94]  H. Lassmann,et al.  Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis , 1998, The Journal of experimental medicine.

[95]  L. Chess,et al.  T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[96]  J S Wolinsky,et al.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.

[97]  C. June,et al.  Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. , 1998 .

[98]  D. Gilden,et al.  Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.

[99]  D. E. Anderson,et al.  Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. , 1998, Journal of immunology.

[100]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[101]  V. Tuohy,et al.  Treatment of Experimental Autoimmune Encephalomyelitis with Genetically Modified Memory T Cells , 1997, The Journal of experimental medicine.

[102]  Larry R. Smith,et al.  Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide , 1997, Journal of Neuroimmunology.

[103]  Larry R. Smith,et al.  Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations , 1997, Journal of Neuroimmunology.

[104]  G. Nolan,et al.  Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis , 1997, The Journal of experimental medicine.

[105]  I. Catz,et al.  The effect of intrathecal MBP synthetic peptides containing epitope P85VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis , 1997, Journal of the Neurological Sciences.

[106]  R. Hohlfeld,et al.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.

[107]  H. Lassmann,et al.  Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. , 1997, The American journal of pathology.

[108]  M. Sela,et al.  Cop 1 as a candidate drug for multiple sclerosis. , 1997, Journal of neural transmission. Supplementum.

[109]  D. Bourdette,et al.  Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial , 1996, Nature Medicine.

[110]  B. Becher,et al.  Immunotherapy for multiple sclerosis: From theory to practice , 1996, Nature Medicine.

[111]  I. Cohen,et al.  Suppressive vaccination with DNA encoding a variable region gene of the T–cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity , 1996, Nature Medicine.

[112]  R. Doms,et al.  Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. , 1996, Journal of immunology.

[113]  D. Hafler,et al.  TCR usage in human and experimental demyelinating disease. , 1996, Immunology today.

[114]  A. Vandenbark,et al.  T cell receptor peptides in treatment of autoimmune disease: Rationale and potential , 1996, Journal of neuroscience research.

[115]  P. Allen,et al.  Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. , 1996, Annual review of immunology.

[116]  D. Wraith Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. , 1995, International archives of allergy and immunology.

[117]  H. Thoenen,et al.  Gene transfer through the blood–nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis , 1995, Nature Medicine.

[118]  P. Stinissen,et al.  Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis , 1995, The Lancet.

[119]  E. Meinl,et al.  Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys. , 1995, International immunology.

[120]  J. Wolinsky Copolymer 1 , 1995, Neurology.

[121]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[122]  R. Ferrante,et al.  In healthy primates, circulating autoreactive T cells mediate autoimmune disease. , 1994, The Journal of clinical investigation.

[123]  D. Bourdette,et al.  Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. , 1994, Journal of immunology.

[124]  D. Bourdette,et al.  Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. , 1994, Journal of immunology.

[125]  H. Weiner,et al.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis , 1994, The Journal of experimental medicine.

[126]  K. Rajewsky,et al.  Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. , 1993, The EMBO journal.

[127]  Norbert,et al.  Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. , 1993, The Journal of clinical investigation.

[128]  D. Hafler,et al.  MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. , 1993, Science.

[129]  E. Sercarz,et al.  Determinant spreading and the dynamics of the autoimmune T-cell repertoire. , 1993, Immunology today.

[130]  A. Begovich,et al.  Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis , 1993, Nature.

[131]  H. Weiner,et al.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. , 1993, Science.

[132]  R. Hohlfeld,et al.  Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor β chain from a myelin basic protein‐specific T cell clone , 1993 .

[133]  M. Sela,et al.  A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis , 1991, Neurology.

[134]  Eric O Long,et al.  A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis , 1991, The Journal of experimental medicine.

[135]  L. Kappos,et al.  Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals , 1990, Neurology.

[136]  L. Kappos,et al.  Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[137]  H. Weiner,et al.  T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis , 1990, Nature.

[138]  A. Begovich,et al.  Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients , 1990, Nature.

[139]  R J Albertini,et al.  T cells responsive to myelin basic protein in patients with multiple sclerosis. , 1990, Science.

[140]  L. Steinman,et al.  The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.

[141]  D. Carlo,et al.  Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. , 1989, Science.

[142]  A. Vandenbark,et al.  Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis , 1989, Nature.

[143]  R. Hohlfeld Neurological autoimmune disease and the trimolecular complex of T‐lymphocytes , 1989, Annals of neurology.

[144]  H. Wekerle,et al.  T cell receptor β chain usage in myelin basic protein‐specific rat T lymphocytes , 1989 .

[145]  A. Ben-nun,et al.  Regulatory circuits in autoimmunity: recruitment of counter‐regulatory CD8+ T cells by encephalitogenic CD4+ T line cells , 1988, European journal of immunology.

[146]  L. Hood,et al.  Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy , 1988, Cell.

[147]  H. Mcdevitt,et al.  Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention , 1988, Cell.

[148]  H. Wekerle,et al.  Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T–T cell interactions , 1988, Nature.

[149]  H. Lassmann,et al.  Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. , 1988, The American journal of pathology.

[150]  H. Weiner,et al.  A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. , 1987, Journal of immunology.

[151]  M. Oldstone Molecular mimicry and autoimmune disease , 1987, Cell.

[152]  S. Wassertheil-Smoller,et al.  A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. , 1987, The New England journal of medicine.

[153]  H. Wekerle,et al.  Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. , 1985, Journal of immunology.

[154]  B. Zweiman,et al.  Isolation of myelin basic protein-reactive T-cell lines from normal human blood. , 1983, Cellular immunology.

[155]  I. Cohen,et al.  Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein , 1981, Nature.

[156]  I. Cohen,et al.  Vaccination against autoimmune encephalomyelitis (EAE): Attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line , 1981, European journal of immunology.

[157]  I. Cohen,et al.  The rapid isolation of clonable antigen‐specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis , 1981, European journal of immunology.